Profile data is unavailable for this security.
About the company
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company’s lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-26.14m
- Incorporated2009
- Employees26.00
- LocationGenprex Inc1601 Trinity StreetBldg. B, Suite 3.322AUSTIN 78712United StatesUSA
- Phone+1 (512) 537-7997
- Fax+1 (302) 655-5049
- Websitehttps://www.genprex.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VBI Vaccines Inc | 9.41m | -83.99m | 717.06k | 131.00 | -- | -- | -- | 0.0762 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
| Entero Therapeutics Inc | 0.00 | -6.44m | 769.75k | 15.00 | -- | 0.0389 | -- | -- | -51.90 | -51.90 | 0.00 | 38.45 | 0.00 | -- | -- | 0.00 | -12.74 | -295.92 | -14.01 | -1,599.51 | -- | -- | -- | -- | -- | -265.69 | 0.0802 | -- | -- | -- | -7.55 | -- | -- | -- |
| Emmaus Life Sciences Inc | 19.97m | -5.26m | 804.71k | 51.00 | -- | -- | -- | 0.0403 | -0.0824 | -0.0824 | 0.2506 | -0.8927 | 0.5239 | 0.5247 | 3.93 | 391,529.40 | -13.79 | -- | -- | -- | 95.48 | -- | -26.32 | -- | 0.1153 | -0.1451 | -- | -- | 60.94 | -- | 64.87 | -- | -- | -- |
| Molecular Pharmacology (USA) Ltd | 0.00 | -105.18k | 899.60k | 0.00 | -- | -- | -- | -- | -0.0009 | -0.0009 | 0.00 | -0.0188 | 0.00 | -- | -- | -- | -976.60 | -1,219.29 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 44.29 | -- | -- | -- |
| Aditxt Inc | 329.75k | -43.31m | 969.17k | 47.00 | -- | 0.0817 | -- | 2.94 | -77.20 | -77.20 | 0.303 | 3.29 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
| PaxMedica Inc | 0.00 | -18.15m | 979.13k | 6.00 | -- | 0.5646 | -- | -- | -11.19 | -11.19 | 0.00 | 0.1594 | 0.00 | -- | -- | 0.00 | -474.77 | -755.77 | -781.78 | -- | -- | -- | -- | -- | -- | -3,015.03 | 0.00 | -- | -- | -- | -23.56 | -- | -- | -- |
| LadRx Corp | 0.00 | -2.77m | 1.06m | 2.00 | -- | -- | -- | -- | -5.59 | -5.59 | 0.00 | -1.89 | 0.00 | -- | -- | 0.00 | -113.62 | -58.97 | -653.73 | -78.44 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 106.96 | -- | -- | -- |
| Genprex Inc | 0.00 | -26.14m | 1.08m | 26.00 | -- | 0.2445 | -- | -- | -16.04 | -16.04 | 0.00 | 1.70 | 0.00 | -- | -- | 0.00 | -232.21 | -92.06 | -318.88 | -98.32 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -29.99 | -- | -7.13 | -- |
| GRI Bio Inc | 0.00 | -8.28m | 1.23m | 4.00 | -- | 0.0714 | -- | -- | -100.69 | -100.69 | 0.00 | 5.88 | 0.00 | -- | -- | 0.00 | -130.64 | -192.93 | -187.01 | -353.99 | -- | -- | -- | -37,650.49 | -- | -- | 0.00 | -- | -- | -- | -85.61 | -- | 29.46 | -- |
| Seelos Therapeutics Inc | 2.01m | 4.09m | 1.33m | 8.00 | 0.0195 | -- | -- | 0.658 | 9.76 | 9.76 | 1.43 | -8.47 | 0.2823 | -- | 6.51 | 134,266.70 | 57.34 | -180.05 | -- | -386.76 | -- | -- | 203.13 | -9,612.88 | -- | -608.33 | -- | -- | -- | -- | 48.48 | -- | -- | -- |
| Regen BioPharma Inc | 236.57k | -882.60k | 1.34m | 1.00 | -- | -- | -- | 5.68 | -0.2157 | -0.2157 | 0.0594 | -1.18 | 1.04 | -- | 3.82 | 236,570.00 | -407.33 | -104.36 | -- | -- | -- | -- | -392.01 | -275.00 | -- | -1.36 | -- | -- | 0.4416 | 18.79 | -58.11 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Armistice Capital LLCas of 30 Jun 2024 | 218.00k | 8.42% |
| Geode Capital Management LLCas of 30 Jun 2024 | 16.50k | 0.64% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 14.98k | 0.58% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 11.39k | 0.44% |
| Tower Research Capital LLCas of 30 Jun 2024 | 3.90k | 0.15% |
| Brown Brothers Harriman & Co. (Investment Management)as of 30 Jun 2024 | 2.50k | 0.10% |
| Group One Trading LPas of 30 Jun 2024 | 828.00 | 0.03% |
| Morgan Stanley & Co. LLCas of 30 Jun 2024 | 791.00 | 0.03% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 696.00 | 0.03% |
| Merrill Lynch International (Investment Management)as of 30 Jun 2024 | 411.00 | 0.02% |
